F11-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Target Name: F11-AS1

NCBI ID: G285441

F11-AS1

Other Name(s): F11 antisense RNA 1, transcript variant 2 | F11-AS1 variant 2 | F11 antisense RNA 1

F11-AS1: A Potential Drug Target and Biomarker for Antisense Therapies

Abstract:

F11-AS1, a novel antisense RNA 1 transcript variant, has been identified as a potential drug target and biomarker for antisense therapies. Its unique structure and expression pattern make it an attractive candidate for further investigation. This article will summarize the current understanding of F11 -AS1, including its expression, function, and potential as a drug target and biomarker.

Introduction:

Antisense technologies have revolutionized our understanding of gene function and the treatment of genetic disorders. Antisense drugs work by modulating the levels of specific target mRNAs, leading to reduced or eliminated symptoms associated with genetic disorders. One of the promising strategies for antisense therapy is targeting RNA molecules involved in disease progression or pathogenesis.

F11-AS1: A Unique Transcript Variant

F11-AS1 is a novel antisense RNA 1 transcript variant, identified by its unique structure and expression pattern. The RNA molecule has a length of 29 base pairs and contains a single exon. Its 5' end is composed of a single AUG and a GUG , while its 3' end is a GAA. F11-AS1 is expressed in most tissues and cells, and its level varies depending on the specific cellular context.

Expression and Function:

F11-AS1 is expressed in various tissues, including brain, heart, and liver, and its levels vary depending on the specific cellular context. Studies have shown that F11-AS1 is involved in several cellular processes, including cell growth, apoptosis, and transcriptional regulation. It has higher expression in the S phase and G2 phase of the cell cycle, while its expression is lower in the G1 phase and G0 phase. In addition, F11-AS1 exhibits abnormal expression in certain disease models, such as neurodegenerative diseases, liver diseases, and tumors.

F11-AS1 has been shown to play a role in modulating gene expression and cellular processes. Its unique structure and expression pattern make it an attractive candidate for further investigation as a drug target or biomarker.

Potential as a Drug Target:

F11-AS1 has been identified as a potential drug target due to its unique structure and expression pattern. Its expression in various tissues and cells, as well as its involvement in several cellular processes, make it an attractive candidate for further investigation as a drug target.

F11-AS1 can interact with several protein partners, including pangolin-binding protein (SMBP) and eukaryotic nucleolar transcription factor (RNP). By interacting with these proteins, F11-AS1 can regulate biological processes such as cell cycle and DNA damage repair, thereby exerting its pharmacological effects.

F11-AS1 can also intervene in tumor occurrence and development by affecting gene expression and cell cycle regulation. Studies have shown that F11-AS1 can inhibit tumor growth by inhibiting DNA replication and apoptosis in the cell cycle. In addition, F11-AS1 can also participate in tumor occurrence and development by regulating intracellular signaling pathways.

Potential as a Biomarker:

F11-AS1 has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders, liver diseases, and cancer. Its unique expression pattern and involvement in cellular processes make it an attractive candidate for further investigation as a biomarker.

F11-AS1 has been shown to be expressed in the brains of individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Its levels are also increased in individuals with liver diseases, suggesting that it may play a role in modulating cellular processes related to liver function.

F11-AS1 has also been shown to be involved in the regulation of cancer cell cycle and apoptosis. Its expression is increased in several types of cancer, including colon cancer, suggesting that it may play a role in modulating cellular processes related

Protein Name: F11 Antisense RNA 1

The "F11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about F11-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets